<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737278</url>
  </required_header>
  <id_info>
    <org_study_id>13MFHM</org_study_id>
    <nct_id>NCT04737278</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Parallel Study Evaluating the Safety and Efficacy of Cunermuspir on Energy, Strength, Fatigue and Discomfort in Subjects With Nerve or Muscle Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitosynergy LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitosynergy LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Male and female participants were selected based on chronic neuromuscular pain. Patients were&#xD;
      instructed to take two doses of the placebo or cuprous nicotinic acid chelate Cunermusmir&#xD;
      twice a day for 28 days. Hypothesis: Cunermuspir would improve quality of life as determined&#xD;
      by several questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 72 subjects were consented and screened, with 56 subjects (28 males and 28 female)&#xD;
      being eligible to participate in the study. Fifty-six subjects with muscle/nerve pain were&#xD;
      randomized at a ratio of 1:1 to one of two treatment groups. To evaluate primary and&#xD;
      secondary objectives, study assessments were conducted at Baseline, and Day 28 Â± 2. The&#xD;
      Individualized Neuromuscular Quality of Life Questionnaire (INQoL), Symptom Impact&#xD;
      Questionnaire (SQIR), Mini-Mental State Examination (MMSE) were completed by participants to&#xD;
      assess physical function, pain, fatigue/energy and cognitive function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2014</start_date>
  <completion_date type="Actual">September 29, 2014</completion_date>
  <primary_completion_date type="Actual">May 28, 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double--blind, placebo controlled, parallel study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The investigational product bottles were labeled according to the requirements of ICH--GCP guidelines and applicable local regulatory guidelines. Investigational products were coded by the unblinded personnel at KGK Synergize who were not involved in the collecting or analyzing of study data. Each package contained a similar label differing only in randomization number.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Neuromuscular Symptoms</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>Quality of life was assessed by using the Individualized Neuromuscular Quality of Life Questionnaire (INQoL) Answers to symptom questions are scored from 0 to 6 or 7 with 0 being &quot;none at all&quot; and and 6 to 7 being &quot;an extreme amount&quot; There are three questions regarding pain. The pain score is (a+b+c)/19 x100. The higher the score, the greater the symptom impact.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet ATP</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>Platelet ATP levels were measured as previously published in the literature.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Household Chores and Neuro Muscular Sumptoms</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>Physical function in performing household chores was assessed using the Revised Symptom Impact Questionnaire (SQIR) For each household chore participants are asked to check 1 of 11 boxes between &quot;no difficulty&quot; and &quot;extremely difficult&quot; No difficulty is scored as 0 and extreme difficulty with the task is scored as 10. The higher the score, the more difficulty experienced performing the chore. Friend &amp; Bennett Arthritis Res &amp; Therapy 2011. Household chores are just one module with 9 questions for a maximum of 90 points. These scores are summed and divided by 3. Module 2 relates to the emotional impact with only two questions for a total of 20 points. Module 3 relates to physical symptoms with a total of ten questions worth a maximum of 100 points. This score is divided by 2. The three modules are summed for a total impact score of 100 points. A score of 0 indicates absolutely no impact and a score of 100 the greatest possible impact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>Cognition is the mental process of knowing, including aspects such as awareness, perception, reasoning, and judgment. The mini-mental state exam (MMSE) puts a number to &quot;cognition.&quot; Any score of 24 or more out of a total 30 points is considered normal cognition. A test taker may be asked to orientate in space and time by recalling aspects of the physical location as well as month, day, year, and perhaps season. Simple mathematical calculations like counting backwards from 100 by seven may also be included. A complex command such as redrawing geometric figures scores six points in this exam. Since none of the participates were cognitively impaired, the investigators decided to make obtaining a perfect score on this exam an outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>heart rate is measured in beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>The diastolic blood pressure was measured in mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>baseline and 28 days after enrollment.</time_frame>
    <description>Systolic blood pressure was measured in mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>baseline and 28 days after enrollment.</time_frame>
    <description>changes measured in g/L blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in the fraction of whole blood occupied by red blood cells measured as L/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WBC</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in white blood cells (WBC) measured in units of 10^9 per liter blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RBC</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in red blood cells (RBC) measured in units of 10^12 per liter blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCV</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in mean corpuscular volume (MCV) measured in units of fL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCH</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in mean corpuscular hemoglobin, measured in units of pg, the average amount of hemoglobin in a single RBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCHC</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>mean corpuscular hemoglobin concentration is the concentration of hemoglobin in a single RBC measured in units of g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RDW</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in the RBC distribution width (RDW) are reported in units of percentage (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in the platelet counts are reported in units of 10^9 per liter blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in neutrophils are reported in units of 10^9 per liter blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in lymphocytes are reported in units of 10^9 per liter blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in monocytes are reported in units of 10^9 per liter blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in eosinophils are reported in units of 10^9 cells per liter blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basophil</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in basophils are reported in units of 10^9 cells per liter blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NLR</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>Changes in the neutrophil to lymphocyte ratio (NLR) are reported as a dimensionless fraction of 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in blood glucose are reported in units of mmol per liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urea</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in renal function as measured by blood urea are reported in units of mmol per liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in creatinine are reported in units of micromol per liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in the estimated glomerular filtration rate (eGFR) are reported in units of mL/min/1.73m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in plasma sodium are reported in units of mmol per liter, reference range is 133-146 mEq/L, same as mM/L bloodbook.com</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in plasma potassium are reported in units of mmol per liter, reference value 3.5-5.4 mmol per liter, bloodbook.com</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chloride</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in plasma chloride are reported in uits of mmol per liter The reference range is 98-106 mmol per liter, bloodbook.com</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in total bilirubin are reported in units of micro moles per liter. Direct: up to 0.4 mg/dL, Total: up to 1.0 mg/dL bloodbook.com, Converts to 6.84-17.1 micro moles per liter. https://unitslab.com/node/37</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in the liver enzyme alanine aminotransferase (ALT) in the blood are reported as units per liter Reference range 1 - 21 units/L bloodbook.com</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in the liver enzyme aspartate aminotransferase (AST) in the blood are reported as units per liter Reference range 7 - 27 units/L bloodbook.com</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GGT</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in the liver enzyme gamma-glutamyl transferase in the blood are reported as units per liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copper</measure>
    <time_frame>baseline and 28 days after enrollment</time_frame>
    <description>changes in copper concentration in the blood are reported in units of micro moles per liter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Neuralgia</condition>
  <condition>Myalgia</condition>
  <arm_group>
    <arm_group_label>Cunermuspir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cunermuspir</intervention_name>
    <description>Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
    <arm_group_label>Cunermuspir</arm_group_label>
    <other_name>cuprous nicotinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>same non-medical ingredients and encapsulation as Intervention 1</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female age 18-75&#xD;
&#xD;
          -  If female, subject is not of child bearing potential. Defined as females who have&#xD;
&#xD;
          -  had a hysterectomy or oophorectomy.&#xD;
&#xD;
          -  bilateral tubal ligation or are post-menopausal (natural or surgically with &gt; 1 year&#xD;
             since last menstruation).&#xD;
&#xD;
          -  Female subject of childbearing potential must agree to use a medically approved method&#xD;
             of birth control and have a negative urine pregnancy test result. Acceptable methods&#xD;
             of birth control include: Hormonal contraceptives including oral contraceptives,&#xD;
             hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing),&#xD;
             injectable contraceptives (Depo--Provera, Lunelle), or hormone implant (Norplant&#xD;
             System), Intrauterine devices, Vasectomy of partner, Total Abstinence&#xD;
&#xD;
          -  Subject has unresolved persistent muscle or nerve pain (muscle or nerve pain&#xD;
             population)&#xD;
&#xD;
          -  Subjects using other therapies for nerve/muscle pain (e.g., exercise, TENS,&#xD;
             acupuncture, exercise, psychotherapy, massage, physiotherapy, etc), must be used at a&#xD;
             stable schedule for 1 month prior to the trial and subject agrees to continue these&#xD;
             therapies at the same schedule during the trial avoiding changes in frequency or&#xD;
             intensity and to record therapies in the study diary&#xD;
&#xD;
          -  Agrees to comply with study procedures&#xD;
&#xD;
          -  Has given voluntary, written, informed consent to participate in&#xD;
&#xD;
          -  the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, breastfeeding, or planning to become pregnant during the&#xD;
             course of the trial&#xD;
&#xD;
          -  Planned surgery during the course of the trial&#xD;
&#xD;
          -  Use of prescription drugs for fibromyalgia or nerve pain (e.g.Lyrica, Cymbalta and&#xD;
             Savella and others).&#xD;
&#xD;
          -  Use of prescription medications for depression, anxiety or other mental disorders&#xD;
&#xD;
          -  Requires the use of prescription drugs to control pain (other than provided rescue&#xD;
             medication)&#xD;
&#xD;
          -  Use of oral or topical prescription or over the counter medications or natural health&#xD;
             products for pain relief 3 days prior to randomization and during the trial (other&#xD;
             than provided rescue medication)&#xD;
&#xD;
          -  Use of natural health products including vitamins and minerals within 3 days prior to&#xD;
             randomization and during the trial&#xD;
&#xD;
          -  Use of blood thinning medications (e.g. warfarin)&#xD;
&#xD;
          -  Chronic lyme disease or chronic parasitic infections&#xD;
&#xD;
          -  Uncontrolled hypertension defined as untreated systolic blood pressure &gt; 160 mmHg&#xD;
             and/or diastolic blood pressure &gt; 100 mmHg&#xD;
&#xD;
          -  Subjects with diabetes&#xD;
&#xD;
          -  History of bleeding disorders, or significant blood loss in the past 3 months&#xD;
&#xD;
          -  Alcohol use &gt;2 standard alcoholic drinks per day and/or alcohol or drug abuse within&#xD;
             the past year&#xD;
&#xD;
          -  Allergy or sensitivity to study supplement ingredients or acetaminophen&#xD;
&#xD;
          -  Participation in a clinical research trial within 30 days prior to randomization&#xD;
&#xD;
          -  Individuals who are cognitively impaired and/or who are unable to give informed&#xD;
             consent&#xD;
&#xD;
          -  Any other condition which in the Investigator's opinion may adversely affect the&#xD;
             subject's ability to complete the study or its measures or which may pose significant&#xD;
             risk to the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KGK Synergize now KGK Science</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <results_first_submitted>February 12, 2021</results_first_submitted>
  <results_first_submitted_qc>March 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2021</results_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Copper</keyword>
  <keyword>nicotinic acid</keyword>
  <keyword>energy</keyword>
  <keyword>strength</keyword>
  <keyword>fatigue</keyword>
  <keyword>nerve pain</keyword>
  <keyword>muscle pain</keyword>
  <keyword>neuralgia</keyword>
  <keyword>myalgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myalgia</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Close collaboration with KGK Synergize/Science will be needed to determine which data can be legally shared. In retrospective analysis of data six years later, raw data in the form of a spreadsheet proved to be extremely valuable.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be shared as soon as Mitosynergy meets the regulatory requirements for sharing.</ipd_time_frame>
    <ipd_access_criteria>Access will be determined by regulatory requirements. Mitosynergy favors as broad access as the law allows. If the law permits access on company websites, Mitosynergy will favor this.</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 56 met the enrollment requirements. Of these only 49 completed the study</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cunermuspir</title>
          <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>failure to complete questionnaire</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cunermuspir</title>
          <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="13.6"/>
                    <measurement group_id="B2" value="48.2" spread="10.4"/>
                    <measurement group_id="B3" value="46.8" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Neuromuscular Symptoms</title>
        <description>Quality of life was assessed by using the Individualized Neuromuscular Quality of Life Questionnaire (INQoL) Answers to symptom questions are scored from 0 to 6 or 7 with 0 being &quot;none at all&quot; and and 6 to 7 being &quot;an extreme amount&quot; There are three questions regarding pain. The pain score is (a+b+c)/19 x100. The higher the score, the greater the symptom impact.</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three patients were lost to followup.Four other patients had testing issues that the study investigators deemed them to be removed from baseline and day 28 analyses. This is why there are not 28 patients represented in baseline whereas there are in toxicology related outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Neuromuscular Symptoms</title>
          <description>Quality of life was assessed by using the Individualized Neuromuscular Quality of Life Questionnaire (INQoL) Answers to symptom questions are scored from 0 to 6 or 7 with 0 being &quot;none at all&quot; and and 6 to 7 being &quot;an extreme amount&quot; There are three questions regarding pain. The pain score is (a+b+c)/19 x100. The higher the score, the greater the symptom impact.</description>
          <population>Three patients were lost to followup.Four other patients had testing issues that the study investigators deemed them to be removed from baseline and day 28 analyses. This is why there are not 28 patients represented in baseline whereas there are in toxicology related outcome measures.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="16.4"/>
                    <measurement group_id="O2" value="43.5" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="18.6"/>
                    <measurement group_id="O2" value="32.7" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>test of the hypothesis that the score on day 28 is different from the baseline score in the Placebo group</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>test of the hypothesis that the score on day 28 is different than the baseline score</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Platelet ATP</title>
        <description>Platelet ATP levels were measured as previously published in the literature.</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>ATP isolated from platelets. Some samples were not used for analysis due to contamination with red blood cells.</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet ATP</title>
          <description>Platelet ATP levels were measured as previously published in the literature.</description>
          <population>ATP isolated from platelets. Some samples were not used for analysis due to contamination with red blood cells.</population>
          <units>nmol / E9 Platelets</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="16.4"/>
                    <measurement group_id="O2" value="42" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" spread="20.1"/>
                    <measurement group_id="O2" value="51.2" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 28. Between group comparison was made using ANCOVA accounting for baseline values, no significance at p&lt;0.05. Within group comparisons were made using the paired Student's t test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Household Chores and Neuro Muscular Sumptoms</title>
        <description>Physical function in performing household chores was assessed using the Revised Symptom Impact Questionnaire (SQIR) For each household chore participants are asked to check 1 of 11 boxes between &quot;no difficulty&quot; and &quot;extremely difficult&quot; No difficulty is scored as 0 and extreme difficulty with the task is scored as 10. The higher the score, the more difficulty experienced performing the chore. Friend &amp; Bennett Arthritis Res &amp; Therapy 2011. Household chores are just one module with 9 questions for a maximum of 90 points. These scores are summed and divided by 3. Module 2 relates to the emotional impact with only two questions for a total of 20 points. Module 3 relates to physical symptoms with a total of ten questions worth a maximum of 100 points. This score is divided by 2. The three modules are summed for a total impact score of 100 points. A score of 0 indicates absolutely no impact and a score of 100 the greatest possible impact.</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three patients were lost to followup.Four other patients had testing issues that the study investigators deemed them to be removed from baseline and day 28 analyses. This is why there are not 28 patients represented in baseline whereas there are in toxicology related outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Household Chores and Neuro Muscular Sumptoms</title>
          <description>Physical function in performing household chores was assessed using the Revised Symptom Impact Questionnaire (SQIR) For each household chore participants are asked to check 1 of 11 boxes between &quot;no difficulty&quot; and &quot;extremely difficult&quot; No difficulty is scored as 0 and extreme difficulty with the task is scored as 10. The higher the score, the more difficulty experienced performing the chore. Friend &amp; Bennett Arthritis Res &amp; Therapy 2011. Household chores are just one module with 9 questions for a maximum of 90 points. These scores are summed and divided by 3. Module 2 relates to the emotional impact with only two questions for a total of 20 points. Module 3 relates to physical symptoms with a total of ten questions worth a maximum of 100 points. This score is divided by 2. The three modules are summed for a total impact score of 100 points. A score of 0 indicates absolutely no impact and a score of 100 the greatest possible impact.</description>
          <population>Three patients were lost to followup.Four other patients had testing issues that the study investigators deemed them to be removed from baseline and day 28 analyses. This is why there are not 28 patients represented in baseline whereas there are in toxicology related outcome measures.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="16.8"/>
                    <measurement group_id="O2" value="34.9" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="10.9"/>
                    <measurement group_id="O2" value="29.3" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison made between placebo and Cunermuspir at baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison made at day 28</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>comparison between baseline and day 28</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognition</title>
        <description>Cognition is the mental process of knowing, including aspects such as awareness, perception, reasoning, and judgment. The mini-mental state exam (MMSE) puts a number to &quot;cognition.&quot; Any score of 24 or more out of a total 30 points is considered normal cognition. A test taker may be asked to orientate in space and time by recalling aspects of the physical location as well as month, day, year, and perhaps season. Simple mathematical calculations like counting backwards from 100 by seven may also be included. A complex command such as redrawing geometric figures scores six points in this exam. Since none of the participates were cognitively impaired, the investigators decided to make obtaining a perfect score on this exam an outcome measure.</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three patients were lost to followup.Four other patients had testing issues that the study investigators deemed them to be removed from baseline and day 28 analyses. This is why there are not 28 patients represented in baseline whereas there are in toxicology related outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Cognition</title>
          <description>Cognition is the mental process of knowing, including aspects such as awareness, perception, reasoning, and judgment. The mini-mental state exam (MMSE) puts a number to &quot;cognition.&quot; Any score of 24 or more out of a total 30 points is considered normal cognition. A test taker may be asked to orientate in space and time by recalling aspects of the physical location as well as month, day, year, and perhaps season. Simple mathematical calculations like counting backwards from 100 by seven may also be included. A complex command such as redrawing geometric figures scores six points in this exam. Since none of the participates were cognitively impaired, the investigators decided to make obtaining a perfect score on this exam an outcome measure.</description>
          <population>Three patients were lost to followup.Four other patients had testing issues that the study investigators deemed them to be removed from baseline and day 28 analyses. This is why there are not 28 patients represented in baseline whereas there are in toxicology related outcome measures.</population>
          <units>participants with perfect score</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>base line between group comparisons</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>heart rate is measured in beats per minute</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>heart rate is measured in beats per minute</description>
          <population>For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3" spread="10.8"/>
                    <measurement group_id="O2" value="68.2" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3" spread="9.7"/>
                    <measurement group_id="O2" value="69.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>The diastolic blood pressure was measured in mm Hg</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>The diastolic blood pressure was measured in mm Hg</description>
          <population>For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" spread="6.4"/>
                    <measurement group_id="O2" value="75.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="7.3"/>
                    <measurement group_id="O2" value="74.6" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The original report from KGK Synergize/Science did not specify if the results are ANCOVA or a between group comparison at 2ay 28</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Systolic blood pressure was measured in mm Hg</description>
        <time_frame>baseline and 28 days after enrollment.</time_frame>
        <population>For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Systolic blood pressure was measured in mm Hg</description>
          <population>For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.7" spread="10.6"/>
                    <measurement group_id="O2" value="114.6" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.5" spread="15.8"/>
                    <measurement group_id="O2" value="112.3" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin</title>
        <description>changes measured in g/L blood</description>
        <time_frame>baseline and 28 days after enrollment.</time_frame>
        <population>For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin</title>
          <description>changes measured in g/L blood</description>
          <population>For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.3" spread="12.9"/>
                    <measurement group_id="O2" value="141.3" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.2" spread="14.3"/>
                    <measurement group_id="O2" value="141.0" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematocrit</title>
        <description>changes in the fraction of whole blood occupied by red blood cells measured as L/L</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Hematocrit</title>
          <description>changes in the fraction of whole blood occupied by red blood cells measured as L/L</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>L/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.411" spread="0.034"/>
                    <measurement group_id="O2" value="0.416" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.416" spread="0.038"/>
                    <measurement group_id="O2" value="0.415" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WBC</title>
        <description>changes in white blood cells (WBC) measured in units of 10^9 per liter blood</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>WBC</title>
          <description>changes in white blood cells (WBC) measured in units of 10^9 per liter blood</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="1.57"/>
                    <measurement group_id="O2" value="5.82" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88" spread="1.81"/>
                    <measurement group_id="O2" value="6.00" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RBC</title>
        <description>changes in red blood cells (RBC) measured in units of 10^12 per liter blood</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>RBC</title>
          <description>changes in red blood cells (RBC) measured in units of 10^12 per liter blood</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>10^12 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" spread="0.38"/>
                    <measurement group_id="O2" value="4.74" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" spread="0.41"/>
                    <measurement group_id="O2" value="4.73" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MCV</title>
        <description>changes in mean corpuscular volume (MCV) measured in units of fL</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three patients were lost to followup.Four other patients had testing issues that the study investigators deemed them to be removed from baseline and day 28 analyses. This is why there are not 28 patients represented in baseline whereas there are in toxicology related outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>MCV</title>
          <description>changes in mean corpuscular volume (MCV) measured in units of fL</description>
          <population>Three patients were lost to followup.Four other patients had testing issues that the study investigators deemed them to be removed from baseline and day 28 analyses. This is why there are not 28 patients represented in baseline whereas there are in toxicology related outcome measures.</population>
          <units>fempto liter per cell</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" spread="3.9"/>
                    <measurement group_id="O2" value="87.7" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" spread="4.3"/>
                    <measurement group_id="O2" value="87.7" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MCH</title>
        <description>changes in mean corpuscular hemoglobin, measured in units of pg, the average amount of hemoglobin in a single RBC</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>MCH</title>
          <description>changes in mean corpuscular hemoglobin, measured in units of pg, the average amount of hemoglobin in a single RBC</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>pg per cell</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" spread="1.64"/>
                    <measurement group_id="O2" value="29.81" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.48" spread="1.69"/>
                    <measurement group_id="O2" value="29.86" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MCHC</title>
        <description>mean corpuscular hemoglobin concentration is the concentration of hemoglobin in a single RBC measured in units of g/L</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>MCHC</title>
          <description>mean corpuscular hemoglobin concentration is the concentration of hemoglobin in a single RBC measured in units of g/L</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342.4" spread="8.2"/>
                    <measurement group_id="O2" value="339.9" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341.2" spread="6.4"/>
                    <measurement group_id="O2" value="340.5" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RDW</title>
        <description>changes in the RBC distribution width (RDW) are reported in units of percentage (%)</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>RDW</title>
          <description>changes in the RBC distribution width (RDW) are reported in units of percentage (%)</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>red cell distribution width %</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.78" spread="0.70"/>
                    <measurement group_id="O2" value="13.80" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.77" spread="0.63"/>
                    <measurement group_id="O2" value="13.93" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelets</title>
        <description>changes in the platelet counts are reported in units of 10^9 per liter blood</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>By day 28 three participants were lost to followup: two in the Cunermuspir group and one in the placebo group. There were issues in handling of one platelet sample in the Cunermuspir group. This brings the number in the Cunermuspir group down to 25 on day 28. For technical reasons, platelet data are missing for subject 021. All other blood cell data are present in this report of data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Platelets</title>
          <description>changes in the platelet counts are reported in units of 10^9 per liter blood</description>
          <population>By day 28 three participants were lost to followup: two in the Cunermuspir group and one in the placebo group. There were issues in handling of one platelet sample in the Cunermuspir group. This brings the number in the Cunermuspir group down to 25 on day 28. For technical reasons, platelet data are missing for subject 021. All other blood cell data are present in this report of data.</population>
          <units>10^9 platelets/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250" spread="62"/>
                    <measurement group_id="O2" value="266" spread="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255" spread="65"/>
                    <measurement group_id="O2" value="269" spread="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophils</title>
        <description>changes in neutrophils are reported in units of 10^9 per liter blood</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophils</title>
          <description>changes in neutrophils are reported in units of 10^9 per liter blood</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="1.06"/>
                    <measurement group_id="O2" value="3.35" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="1.19"/>
                    <measurement group_id="O2" value="3.60" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison of neutrophils from baseline to day 28</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphocyte</title>
        <description>changes in lymphocytes are reported in units of 10^9 per liter blood</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphocyte</title>
          <description>changes in lymphocytes are reported in units of 10^9 per liter blood</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="0.64"/>
                    <measurement group_id="O2" value="1.83" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.72"/>
                    <measurement group_id="O2" value="1.74" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monocyte</title>
        <description>changes in monocytes are reported in units of 10^9 per liter blood</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Monocyte</title>
          <description>changes in monocytes are reported in units of 10^9 per liter blood</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.450" spread="0.137"/>
                    <measurement group_id="O2" value="0.475" spread="0.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.473" spread="0.176"/>
                    <measurement group_id="O2" value="0.500" spread="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison of baseline values</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison performed on data from day 28</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eosinophil</title>
        <description>changes in eosinophils are reported in units of 10^9 cells per liter blood</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Eosinophil</title>
          <description>changes in eosinophils are reported in units of 10^9 cells per liter blood</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.154" spread="0.074"/>
                    <measurement group_id="O2" value="0.143" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.181" spread="0.110"/>
                    <measurement group_id="O2" value="0.130" spread="0.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison of eosinophil counts at day 28</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basophil</title>
        <description>changes in basophils are reported in units of 10^9 cells per liter blood</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Basophil</title>
          <description>changes in basophils are reported in units of 10^9 cells per liter blood</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0107" spread="0.0315"/>
                    <measurement group_id="O2" value="0.0071" spread="0.0262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0077" spread="0.0272"/>
                    <measurement group_id="O2" value="0.0074" spread="0.0267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The day 28 basophil counts on day 28 were compared between the two arms of this study.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NLR</title>
        <description>Changes in the neutrophil to lymphocyte ratio (NLR) are reported as a dimensionless fraction of 1</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>NLR</title>
          <description>Changes in the neutrophil to lymphocyte ratio (NLR) are reported as a dimensionless fraction of 1</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>dimensionaless units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.15"/>
                    <measurement group_id="O2" value="1.90" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.14"/>
                    <measurement group_id="O2" value="2.24" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All other statistical analyses were performed by KGK Synergize. This site was used to determine that the NLR were normally distributed https://www.gigacalculator.com/calculators/normality-test-calculator.php&#xD;
Because these data fulfilled the assumptions of ANOVA, the data were analyzed using this site:&#xD;
http://vassarstats.net/anova2u.html</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>This p value is for the treatment source. Visits (p=0.422) and visits x treatments (p=0.153) did not meet the threshold of significance.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose</title>
        <description>changes in blood glucose are reported in units of mmol per liter</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>In this population the initial screening was considered the baseline for all blood chemistry parameters. Three of the the participants were lost to followup or withdrew from the study</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose</title>
          <description>changes in blood glucose are reported in units of mmol per liter</description>
          <population>In this population the initial screening was considered the baseline for all blood chemistry parameters. Three of the the participants were lost to followup or withdrew from the study</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.12" spread="0.55"/>
                    <measurement group_id="O2" value="5.30" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" spread="0.44"/>
                    <measurement group_id="O2" value="5.24" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison of blood glucose in the Cunermuspir arm between enrollment baseline and day 28.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of enrollment baseline blood glucose and day 28 in the placebo arm</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urea</title>
        <description>changes in renal function as measured by blood urea are reported in units of mmol per liter</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Urea</title>
          <description>changes in renal function as measured by blood urea are reported in units of mmol per liter</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.16" spread="1.13"/>
                    <measurement group_id="O2" value="5.33" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" spread="1.57"/>
                    <measurement group_id="O2" value="5.26" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine</title>
        <description>changes in creatinine are reported in units of micromol per liter</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine</title>
          <description>changes in creatinine are reported in units of micromol per liter</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>micromol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" spread="11.6"/>
                    <measurement group_id="O2" value="72.9" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" spread="13.7"/>
                    <measurement group_id="O2" value="73.7" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>eGFR</title>
        <description>changes in the estimated glomerular filtration rate (eGFR) are reported in units of mL/min/1.73m^2</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>eGFR</title>
          <description>changes in the estimated glomerular filtration rate (eGFR) are reported in units of mL/min/1.73m^2</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.4" spread="17.3"/>
                    <measurement group_id="O2" value="88.8" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" spread="18.3"/>
                    <measurement group_id="O2" value="85.9" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sodium</title>
        <description>changes in plasma sodium are reported in units of mmol per liter, reference range is 133-146 mEq/L, same as mM/L bloodbook.com</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Sodium</title>
          <description>changes in plasma sodium are reported in units of mmol per liter, reference range is 133-146 mEq/L, same as mM/L bloodbook.com</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.39" spread="2.25"/>
                    <measurement group_id="O2" value="143.14" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.62" spread="2.47"/>
                    <measurement group_id="O2" value="141.89" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Blood sodium concentration between baseline and day 28 in the Placebo group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potassium</title>
        <description>changes in plasma potassium are reported in units of mmol per liter, reference value 3.5-5.4 mmol per liter, bloodbook.com</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>The study sponsor is of the opinion that these participants were dehydrated when they started the study. They were instructed to drink more water. Three of the 56 that started the study were lost to followup or withdrew.</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Potassium</title>
          <description>changes in plasma potassium are reported in units of mmol per liter, reference value 3.5-5.4 mmol per liter, bloodbook.com</description>
          <population>The study sponsor is of the opinion that these participants were dehydrated when they started the study. They were instructed to drink more water. Three of the 56 that started the study were lost to followup or withdrew.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" spread="0.45"/>
                    <measurement group_id="O2" value="4.84" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" spread="0.43"/>
                    <measurement group_id="O2" value="4.39" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>comparison of blood potassium concentration upon enrollment and day 28 in the Cunermuspir participants</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison of blood potassium concentrations from enrollment to day 28 in participants in the Placebo arm.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chloride</title>
        <description>changes in plasma chloride are reported in uits of mmol per liter The reference range is 98-106 mmol per liter, bloodbook.com</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Enrollment pre-screening values are taken as the baseline. The study sponsor was of the opinion that these participants started the study dehydrated. Of the original 56 three were lost to followup or withdrew.</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Chloride</title>
          <description>changes in plasma chloride are reported in uits of mmol per liter The reference range is 98-106 mmol per liter, bloodbook.com</description>
          <population>Enrollment pre-screening values are taken as the baseline. The study sponsor was of the opinion that these participants started the study dehydrated. Of the original 56 three were lost to followup or withdrew.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.14" spread="2.12"/>
                    <measurement group_id="O2" value="106.43" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.08" spread="2.23"/>
                    <measurement group_id="O2" value="105.15" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>comparison between baseline and day 28 chloride concentrations in the Cunermuspir group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison of blood chloride concentrations between baseline and day 28 in Placebo Arm participants</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin</title>
        <description>changes in total bilirubin are reported in units of micro moles per liter. Direct: up to 0.4 mg/dL, Total: up to 1.0 mg/dL bloodbook.com, Converts to 6.84-17.1 micro moles per liter. https://unitslab.com/node/37</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin</title>
          <description>changes in total bilirubin are reported in units of micro moles per liter. Direct: up to 0.4 mg/dL, Total: up to 1.0 mg/dL bloodbook.com, Converts to 6.84-17.1 micro moles per liter. https://unitslab.com/node/37</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>micromol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="5.9"/>
                    <measurement group_id="O2" value="9.3" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="5.9"/>
                    <measurement group_id="O2" value="9.9" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bilirubin concentrations between Placebo and Cunermuspir compared at day 28</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>comparison of bilirubin concentrations between baseline and day 28 in the Cunermuspir Arm</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon Signed-Rank</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>bilirubin concentrations compared between baseline and Day 28 in the Placebo Arm</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT</title>
        <description>changes in the liver enzyme alanine aminotransferase (ALT) in the blood are reported as units per liter Reference range 1 - 21 units/L bloodbook.com</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>ALT</title>
          <description>changes in the liver enzyme alanine aminotransferase (ALT) in the blood are reported as units per liter Reference range 1 - 21 units/L bloodbook.com</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="12.8"/>
                    <measurement group_id="O2" value="28.5" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" spread="15.5"/>
                    <measurement group_id="O2" value="28.4" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>comparison between baseline and day 28 values in Cunermuspir group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison between baseline and day 28 values for the Placebo Arm</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST</title>
        <description>changes in the liver enzyme aspartate aminotransferase (AST) in the blood are reported as units per liter Reference range 7 - 27 units/L bloodbook.com</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>AST</title>
          <description>changes in the liver enzyme aspartate aminotransferase (AST) in the blood are reported as units per liter Reference range 7 - 27 units/L bloodbook.com</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="4.9"/>
                    <measurement group_id="O2" value="23.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="6.2"/>
                    <measurement group_id="O2" value="25.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison of AST enzyme activity in blood on day 28 between Cunermuspir and Placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>baseline to day 28 comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>baseline to day 28 comparison of AST activity in Placebo group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GGT</title>
        <description>changes in the liver enzyme gamma-glutamyl transferase in the blood are reported as units per liter</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>GGT</title>
          <description>changes in the liver enzyme gamma-glutamyl transferase in the blood are reported as units per liter</description>
          <population>Three participants were lost to followup on day 28. For toxicology outcome measures the investigators included all 28 participants in each group at baseline as well as data for the 26 (Cunermuspir) and 27 (Placebo) remaining at day 28. The investigators considered these data valid in spite of issues with the questionnaires of other outcome measures</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="13.6"/>
                    <measurement group_id="O2" value="28.6" spread="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="18.1"/>
                    <measurement group_id="O2" value="25.6" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison between placebo and Cunermuspir at day 28</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <p_value_desc>Comparison of GGT activities in blood of two arms: Cunermuspir and Placebo on Day 28</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison of GGT activities in participants' blood at baseline and on day 28</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon Signed Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of GGT activity in blood between Placebo Arm participants at baseline and on day 28</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Wilcoxon Signed-Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Copper</title>
        <description>changes in copper concentration in the blood are reported in units of micro moles per liter</description>
        <time_frame>baseline and 28 days after enrollment</time_frame>
        <population>Of the 56 enrolled in the study three were lost to followup or dropped out.</population>
        <group_list>
          <group group_id="O1">
            <title>Cunermuspir</title>
            <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
          </group>
        </group_list>
        <measure>
          <title>Copper</title>
          <description>changes in copper concentration in the blood are reported in units of micro moles per liter</description>
          <population>Of the 56 enrolled in the study three were lost to followup or dropped out.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.18" spread="2.42"/>
                    <measurement group_id="O2" value="17.62" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="2.8"/>
                    <measurement group_id="O2" value="17.57" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between group comparisons were made using ANCOVA</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>comparison of baseline with day 28</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison between baseline and day 28 serum copper concentrations in the Placebo Arm</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <desc>All treatment--emergent adverse events (AEs) are listed and MedDRA--coded to obtain the MedDRA Preferred Term and Organ System (&quot;body system&quot;). The nature, incidence, severity and causality were AEs were summarized in a frequency table, by body system and treatment. The proportion of subjects experiencing one or more AEs were compared between groups, separately for each body system and for all AEs combined.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cunermuspir</title>
          <description>Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.&#xD;
Cunermuspir: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:&#xD;
Organic evaporated cane juice powder, hypromellose, titanium dioxide</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm&#xD;
Placebo: same non-medical ingredients and encapsulation as Intervention 1</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nasea</sub_title>
                <description>also includes upset stomach, dry mouth, and dry mouth</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>seasonal respiratory infections</sub_title>
                <description>includes sinusitis, common cold, and flu</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>head ache</sub_title>
                <description>the study investigators concluded that on of the two head ache in the Cunermuspir Arm may have been related to the study product.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>moderate dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The study PI (Dale Wilson) retired soon after the study was completed. KGK Synergize has undergone reorganization as KGK Science. The original intent was to publish the study results in a peer review journal.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Barbara Leinweber, PhD</name_or_title>
      <organization>BDL Biochemistry, consultant for Mitosynergy</organization>
      <phone>(520)334-5444</phone>
      <email>barb@bdlbiochem.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

